Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T16:18:02.243Z.
Calculation as of: 2026-10-06T16:18:02.243Z.
Quote observation: 2026-10-06T16:11:35.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 7269c43ec051f04bc9b25698fa87f96476c1bd81d443a59abbb4ab2a9593cf8e
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
NeuroSense Therapeutics Ltd.
Market Cap
$7.08M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$7.07M
EV/Sales Ratio
N/A
TTM Avg
1044.91x
3Y Avg
1288.72x
5Y Avg
2112.32x
Market Cap
$7.07M
EV/Sales Ratio
22.74x
TTM Avg
19.77x
3Y Avg
15.30x
5Y Avg
133.58x
Market Cap
$7.20M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$7.31M
EV/Sales Ratio
0.00x
TTM Avg
0.29x
3Y Avg
0.29x
5Y Avg
1.64x
Market Cap
$6.80M
EV/Sales Ratio
3.31x
TTM Avg
3.30x
3Y Avg
4.62x
5Y Avg
27.01x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| NeuroSense Therapeutics Ltd. (NRSN) | $7.08M | N/A | N/A | N/A | N/A |
| KALA BIO, Inc. (KALA)vs › | $7.07M | N/A | 1044.91x | 1288.72x | 2112.32x |
| Mangoceuticals, Inc. (MGRX)vs › | $7.07M | 22.74x | 19.77x | 15.30x | 133.58x |
| Curanex Pharmaceuticals Inc Common Stock (CURX)vs › | $7.20M | N/A | N/A | N/A | N/A |
| InMed Pharmaceuticals Inc. (INM)vs › | $7.31M | 0.00x | 0.29x | 0.29x | 1.64x |
| Longeveron Inc. (LGVN)vs › | $7.33M | N/A | 5.06x | 10.00x | 33.75x |
| Bolt Biotherapeutics, Inc. (BOLT)vs › | $6.80M | 3.31x | 3.30x | 4.62x | 27.01x |
| Aclarion, Inc. (ACON)vs › | $6.74M | N/A | 36.65x | 72.84x | 72.84x |
| CNS Pharmaceuticals, Inc. (CNSP)vs › | $7.37M | N/A | N/A | N/A | N/A |
| Co-Diagnostics, Inc. (CODX)vs › | $6.69M | 6.71x | 5.17x | 3.61x | 2.57x |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
